Results 111 to 120 of about 14,439 (224)
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Is Australia ready for biosimilars? [PDF]
The biosimilars market is potentially the single fastest growing pharmaceutical sector with an estimated worth of US$67bn in global sales by 2020. This market generally refers to larger molecule, biological, protein-based pharmaceuticals which have lost
Hepworth, Julie +2 more
core +1 more source
Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan
Background Biosimilars present a significant opportunity for cost savings. However, the uptake of biosimilars has been inconsistent across different regions and drugs, highlighting the need for effective policy interventions.
Hiroaki Mamiya +2 more
doaj +1 more source
ABSTRACT Rationale Non‐reduced trypsin digestion of therapeutic antibodies can generate large disulfide‐linked peptide complexes that exhibit poor chromatographic and mass spectrometric performance. This limits the confident characterization of posttranslational modifications (PTMs) in specific antibody regions, such as the heavy‐chain constant region ...
Nanna Sofie Eskesen +10 more
wiley +1 more source
INTRODUCTION: Rituximab is a monoclonal antibody targeting CD20, used to treat B cell malignancies and B cell-mediated autoimmune diseases. Rituximab has the largest market of any monoclonal antibody therapeutic.
Kay, Jonathan +2 more
core +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
Beyond Drugs or Surgery: Precision and Equity in Obesity Care
Diabetes, Obesity and Metabolism, EarlyView.
Ron T. Varghese +4 more
wiley +1 more source
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher +12 more
wiley +1 more source
Capacity building in medicines development and regulation in Africa—Overview on recent progress
Aims Despite advances in health research and digital innovation, many African countries continue to face substantial resource constraints, fragmented capacity‐building efforts and a shortage of skilled professionals in medicines development and regulatory science.
Tirhani Maluleke +7 more
wiley +1 more source
BIOLOGICALS AND BIOSIMILARS: AN OVERVIEW
Biologics are highly sensitive large molecules with complex structure, difficult to characterize and reproduce, derived from living cells; used for treatment, diagnosis or prevention of disease. .
K. Ravi Shankar and K.P.R. Chowdary
core +1 more source

